Wird geladen...
JAK kinase inhibitors for the treatment of acute lymphoblastic leukemia
Recent studies of acute lymphoblastic leukemia have identified activating mutations in components of the interleukin-7 receptor complex (IL7R, JAK1, and JAK3). It will be of interest to investigate both JAK1 and JAK3 kinase inhibitors as targeted agents for these leukemias.
Gespeichert in:
| Veröffentlicht in: | J Hematol Oncol |
|---|---|
| Hauptverfasser: | , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
BioMed Central
2015
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4545857/ https://ncbi.nlm.nih.gov/pubmed/26208852 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-015-0192-7 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|